PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9481447

Recombinant coagulation factors.

P H Roddie·C A Ludlam
View original source ↗Export metadata ↓

Abstract

The advent of technology that has allowed production of recombinant proteins on an industrial scale has revolutionized haemophilia care. Recombinant coagulation factors, as opposed to their plasma-derived counterparts, have a very low risk for transmission of infectious agents and their use should eradicate the threat of infection from viruses such as hepatitis C and the human immunodeficiency virus. This review outlines the manufacturing process involved in the production of the recombinant coagulation factors and the trials to date that have been performed to establish their safety and efficacy. We also discuss some of the issues involved in the change to use of recombinant coagulation factors, such as viral safety and potential immunogenicity.

Explore related subjects

Blood Coagulation FactorsFactor IXFactor VIIIFactor VIIaHumansRecombinant ProteinsJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P H Roddie, C A Ludlam. 1997. Recombinant coagulation factors.. https://doi.org/10.1016/s0268-960x(97)90017-5

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Prophylactic treatment of a small child with severe factor VII deficiency using repeat dosing from a single vial of recombinant activated factor VII.

We report our experience with a small child with severe factor VII deficiency and a history of frequent and spontaneous life-threatening hemorrhage. The patient has received several years of successful prophylactic treatment with an every 3-day infusion program in which she receives recombinant activated factor VII (rVIIa) using multiple doses from a single reconstituted vial over a 72-hr period. Comparison is made to prophylactic treatment in this same patient using plasma-derived factor VII (PDVII) using a prothrombin complex concentrate (PCC).

Blood Coagulation Factors↗
PubMed2007

Heparin-induced inhibitory effects of a prothrombin complex concentrate on global tests of haemostasis.

Prothrombin complex concentrates (PCC) have been used as bypassing agents for the treatment of haemophilia A patients with inhibitor as well as for replacement therapy in congenital and acquired deficiencies of vitamin-K-dependent clotting factors. The efficacy of PCC is variable, however, especially during long-term and high-dose use, and all currently available products of this nature contain heparin. We have examined the haemostatic properties of PCC using reconstituted whole blood made by mixing coagulation-factor-deficient plasma and washed blood cells. In rotation thromboelastometry (ROTEM), the recommended therapeutic dose of Proplex ST corrected the abnormal patterns. At higher concentrations, however, the ROTEM patterns regressed. In addition, specific assays of coagulation factors appeared unreliable in the presence of 2.5 U/ml Proplex ST; the abnormalities were corrected when protamine sulfate was added. The findings suggest that the presence of heparin in PCC might have a greater effect on global haemostasis. Careful attention to the anticoagulant effect as well as thrombogenicity of PCC is required. Monitoring therapy using such as ROTEM analysis could be highly informative.

Blood Coagulation Factors↗